Cargando…
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of treatmen...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556323/ https://www.ncbi.nlm.nih.gov/pubmed/36138152 http://dx.doi.org/10.1038/s41591-022-01969-y |
_version_ | 1784807051403198464 |
---|---|
author | Bachy, Emmanuel Le Gouill, Steven Di Blasi, Roberta Sesques, Pierre Manson, Guillaume Cartron, Guillaume Beauvais, David Roulin, Louise Gros, François Xavier Rubio, Marie Thérèse Bories, Pierre Bay, Jacques Olivier Llorente, Cristina Castilla Choquet, Sylvain Casasnovas, René-Olivier Mohty, Mohamad Guidez, Stéphanie Joris, Magalie Loschi, Michaël Carras, Sylvain Abraham, Julie Chauchet, Adrien Drieu La Rochelle, Laurianne Deau-Fischer, Bénédicte Hermine, Olivier Gastinne, Thomas Tudesq, Jean Jacques Gat, Elodie Broussais, Florence Thieblemont, Catherine Houot, Roch Morschhauser, Franck |
author_facet | Bachy, Emmanuel Le Gouill, Steven Di Blasi, Roberta Sesques, Pierre Manson, Guillaume Cartron, Guillaume Beauvais, David Roulin, Louise Gros, François Xavier Rubio, Marie Thérèse Bories, Pierre Bay, Jacques Olivier Llorente, Cristina Castilla Choquet, Sylvain Casasnovas, René-Olivier Mohty, Mohamad Guidez, Stéphanie Joris, Magalie Loschi, Michaël Carras, Sylvain Abraham, Julie Chauchet, Adrien Drieu La Rochelle, Laurianne Deau-Fischer, Bénédicte Hermine, Olivier Gastinne, Thomas Tudesq, Jean Jacques Gat, Elodie Broussais, Florence Thieblemont, Catherine Houot, Roch Morschhauser, Franck |
author_sort | Bachy, Emmanuel |
collection | PubMed |
description | Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of treatment who had a commercial chimeric antigen receptor (CAR) T cells order for axi-cel or tisa-cel and were registered in the retrospective French DESCAR-T registry study (NCT04328298). After 1:1 propensity score matching (n = 418), the best overall response rate/complete response rate (ORR/CRR) was 80%/60% versus 66%/42% for patients treated with axi-cel compared to tisa-cel, respectively (P < 0.001 for both ORR and CRR comparisons). After a median follow-up of 11.7 months, the 1-year progression-free survival was 46.6% for axi-cel and 33.2% for tisa-cel (hazard ratio (HR) = 0.61; 95% confidence interval (CI), 0.46–0.79; P = 0.0003). Overall survival (OS) was also significantly improved after axi-cel infusion compared to after tisa-cel infusion (1-year OS 63.5% versus 48.8%; HR = 0.63; 95% CI, 0.45–0.88; P = 0.0072). Similar findings were observed using the inverse probability of treatment weighting statistical approach. Grade 1–2 cytokine release syndrome was significantly more frequent with axi-cel than with tisa-cel, but no significant difference was observed for grade ≥3. Regarding immune effector cell-associated neurotoxicity syndrome (ICANS), both grade 1–2 and grade ≥3 ICANS were significantly more frequent with axi-cel than with tisa-cel. In conclusion, our matched comparison study supports a higher efficacy and also a higher toxicity of axi-cel compared to tisa-cel in the third or more treatment line for R/R DLBCL. |
format | Online Article Text |
id | pubmed-9556323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-95563232022-10-14 A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma Bachy, Emmanuel Le Gouill, Steven Di Blasi, Roberta Sesques, Pierre Manson, Guillaume Cartron, Guillaume Beauvais, David Roulin, Louise Gros, François Xavier Rubio, Marie Thérèse Bories, Pierre Bay, Jacques Olivier Llorente, Cristina Castilla Choquet, Sylvain Casasnovas, René-Olivier Mohty, Mohamad Guidez, Stéphanie Joris, Magalie Loschi, Michaël Carras, Sylvain Abraham, Julie Chauchet, Adrien Drieu La Rochelle, Laurianne Deau-Fischer, Bénédicte Hermine, Olivier Gastinne, Thomas Tudesq, Jean Jacques Gat, Elodie Broussais, Florence Thieblemont, Catherine Houot, Roch Morschhauser, Franck Nat Med Article Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of treatment who had a commercial chimeric antigen receptor (CAR) T cells order for axi-cel or tisa-cel and were registered in the retrospective French DESCAR-T registry study (NCT04328298). After 1:1 propensity score matching (n = 418), the best overall response rate/complete response rate (ORR/CRR) was 80%/60% versus 66%/42% for patients treated with axi-cel compared to tisa-cel, respectively (P < 0.001 for both ORR and CRR comparisons). After a median follow-up of 11.7 months, the 1-year progression-free survival was 46.6% for axi-cel and 33.2% for tisa-cel (hazard ratio (HR) = 0.61; 95% confidence interval (CI), 0.46–0.79; P = 0.0003). Overall survival (OS) was also significantly improved after axi-cel infusion compared to after tisa-cel infusion (1-year OS 63.5% versus 48.8%; HR = 0.63; 95% CI, 0.45–0.88; P = 0.0072). Similar findings were observed using the inverse probability of treatment weighting statistical approach. Grade 1–2 cytokine release syndrome was significantly more frequent with axi-cel than with tisa-cel, but no significant difference was observed for grade ≥3. Regarding immune effector cell-associated neurotoxicity syndrome (ICANS), both grade 1–2 and grade ≥3 ICANS were significantly more frequent with axi-cel than with tisa-cel. In conclusion, our matched comparison study supports a higher efficacy and also a higher toxicity of axi-cel compared to tisa-cel in the third or more treatment line for R/R DLBCL. Nature Publishing Group US 2022-09-22 2022 /pmc/articles/PMC9556323/ /pubmed/36138152 http://dx.doi.org/10.1038/s41591-022-01969-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Bachy, Emmanuel Le Gouill, Steven Di Blasi, Roberta Sesques, Pierre Manson, Guillaume Cartron, Guillaume Beauvais, David Roulin, Louise Gros, François Xavier Rubio, Marie Thérèse Bories, Pierre Bay, Jacques Olivier Llorente, Cristina Castilla Choquet, Sylvain Casasnovas, René-Olivier Mohty, Mohamad Guidez, Stéphanie Joris, Magalie Loschi, Michaël Carras, Sylvain Abraham, Julie Chauchet, Adrien Drieu La Rochelle, Laurianne Deau-Fischer, Bénédicte Hermine, Olivier Gastinne, Thomas Tudesq, Jean Jacques Gat, Elodie Broussais, Florence Thieblemont, Catherine Houot, Roch Morschhauser, Franck A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma |
title | A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma |
title_full | A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma |
title_fullStr | A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma |
title_full_unstemmed | A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma |
title_short | A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma |
title_sort | real-world comparison of tisagenlecleucel and axicabtagene ciloleucel car t cells in relapsed or refractory diffuse large b cell lymphoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556323/ https://www.ncbi.nlm.nih.gov/pubmed/36138152 http://dx.doi.org/10.1038/s41591-022-01969-y |
work_keys_str_mv | AT bachyemmanuel arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT legouillsteven arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT diblasiroberta arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT sesquespierre arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT mansonguillaume arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT cartronguillaume arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT beauvaisdavid arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT roulinlouise arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT grosfrancoisxavier arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT rubiomarietherese arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT boriespierre arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT bayjacquesolivier arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT llorentecristinacastilla arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT choquetsylvain arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT casasnovasreneolivier arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT mohtymohamad arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT guidezstephanie arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT jorismagalie arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT loschimichael arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT carrassylvain arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT abrahamjulie arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT chauchetadrien arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT drieularochellelaurianne arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT deaufischerbenedicte arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT hermineolivier arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT gastinnethomas arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT tudesqjeanjacques arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT gatelodie arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT broussaisflorence arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT thieblemontcatherine arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT houotroch arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT morschhauserfranck arealworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT bachyemmanuel realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT legouillsteven realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT diblasiroberta realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT sesquespierre realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT mansonguillaume realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT cartronguillaume realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT beauvaisdavid realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT roulinlouise realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT grosfrancoisxavier realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT rubiomarietherese realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT boriespierre realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT bayjacquesolivier realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT llorentecristinacastilla realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT choquetsylvain realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT casasnovasreneolivier realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT mohtymohamad realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT guidezstephanie realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT jorismagalie realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT loschimichael realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT carrassylvain realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT abrahamjulie realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT chauchetadrien realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT drieularochellelaurianne realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT deaufischerbenedicte realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT hermineolivier realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT gastinnethomas realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT tudesqjeanjacques realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT gatelodie realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT broussaisflorence realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT thieblemontcatherine realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT houotroch realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma AT morschhauserfranck realworldcomparisonoftisagenlecleucelandaxicabtageneciloleucelcartcellsinrelapsedorrefractorydiffuselargebcelllymphoma |